However, while clinical trial results showed that neutralizing titers that exceeded the response to natural infection were elicited by the two adjuvanted subunit protein candidates that were advanced to efficacy trials (one comprised of HSV-2 glycoprotein D (gD-2) and glycoprotein B (gB-2) with the adjuvant MF59 and the other, gD-2 with the adjuvant AS04), there was no significant protection against infection or disease [2,3]. The gene discussed is ACKR1; the disease is infection.